Skip to main content
Skip to content
Cannabis Science Overview – Plant Tissue Cultures and DosingCannabis Industry Segmentation Report – No Direct Links to Powerful Actors
Case File
kaggle-ho-024666House Oversight

Cannabis Investment Report dosage chart with medical claims

Cannabis Investment Report dosage chart with medical claims The passage is a generic dosage table for cannabis products with no mention of specific individuals, agencies, financial transactions, or controversial actions. It offers no actionable leads for investigation and contains only publicly known medical information. Key insights: Provides THC and CBD dosage ranges for various conditions.; Lists potential short‑ and long‑term side effects of cannabis.; Attributed to Ackrell Capital, a FINRA‑registered firm.

Date
Unknown
Source
House Oversight
Reference
kaggle-ho-024666
Pages
1
Persons
0
Integrity
No Hash Available

Summary

Cannabis Investment Report dosage chart with medical claims The passage is a generic dosage table for cannabis products with no mention of specific individuals, agencies, financial transactions, or controversial actions. It offers no actionable leads for investigation and contains only publicly known medical information. Key insights: Provides THC and CBD dosage ranges for various conditions.; Lists potential short‑ and long‑term side effects of cannabis.; Attributed to Ackrell Capital, a FINRA‑registered firm.

Tags

kagglehouse-oversightcannabismedical-dosageinvestment-report
View on oversight.house.gov

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
Cannabis Investment Report | December 2017 Representative Dosage Amounts Desired Effect or Ailment Dosage “High” 10 mg THC Anxiety, depression, spasms 25 mg CBD Cancer 25 mg CBD Chronic pain 2.5-20 mg THC Epileptic seizures 200-300 mg CBD Glaucoma 20-40 mg CBD Increased appetite 2.5 mg THC Multiple sclerosis 2.5-120 mg THC 40-1,280 mg CBD 40-160 mg CBD Schizophrenia Sleep disorders Neither the potential medicinal benefits and therapeutic Dosage Ratio (THC:CBD) 10:1 to 100:1 1:10 1:1 10:1 1:5 1:2 to 1:4 5:1 1:1 1:4 to 1:128 1:4 to 1:16 applications of cannabis consumption nor the negative side effects of cannabis use have been thoroughly researched by medical science. Short- term negative side effects are believed by some to include sensory distortion, panic, anxiety, poor coor- dination of movement, reduced reaction time, lethargy or drowsiness, depression and elevated heart rate. Longer-term effects may include suppression of the immune system, growth disorders, destruc- tion of lung fibers, brain lesions, reduced sexual capacity, difficulties with concentration, reduced abil- ity to learn and retain information, and personality and moo about whether cannabis consumption may lead to the abuse “gateway drug” debate). 30 d changes. There is also an ongoing debate of more harmful substances (the so-called © 2017 Ackrell Capital, LLC | Member FINRA/SIPC

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.